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Abstract 
Ectoparasites are found widely distributed in all agro-ecological zones of Ethiopia. The problems they cause can 
be alleviated through the use of traditional medicinal plants.  Cymbopogon citratus is one of the traditional herbs 
commonly used for such purpose.  This study was conducted to profile safety of the C. citratus based anti 
ectoparasitic formulation. The toxicity study had shown significant weight change in animal group that received 
3.75% of the formulation. There were also significant changes in serum lipid profiles of treated group animals 
compared with the control. The level of uric acid in animals treated with 3.75% of the formulation showed 
significant increase compared with the control.  
------------------------------------------------------------------------ 
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Liver and kidney histopathology of both treatment group animals revealed few mononuclear leucocytic 
infiltrations.  The blood cell parameters and different biochemical findings had revealed no sign of toxicity. 
However; other measured parameters like the body weight, histological and some biochemical findings had 
shown both significant and insignificant sign of toxicities.  Therefore; it is important to consider the effect of the 
formulation in prolonged treatment on body weight, uric acid excretion and lipid metabolism. 
Key words: Cymbopogon citratus; anti-ectoparasite; medicinal plants; Sub-chronic toxicity; histopathology. 
1. Introduction 
The plant based traditional medicines appear most promising; and they are culturally ingrained, accessible, and 
affordable. About 70% to 95% of population in many developing countries, including Ethiopia use and rely on 
them as a primary source for both human and veterinary medicine [23]. Ethiopia is considered as having the 
largest livestock population in Africa and currently considered as the biggest exporter in the continent [14, 22]. 
Ectoparasites including lice, sheep keds, ticks, fleas and mange mites commonly cause a wide range of health 
problems on livestock population [11, 24, 21]. Infestations from these ectoparasites induce great economic 
losses by reducing wool quality, meat and milk yield, and related with cost of treatment [21].  Cymbopogon 
citratus is an economically important plant belonging to Family: Poaceae, Genus: Cymbopogon, specific 
epithet: citratus. It is commonly called lemon grass in English. Its linear leaves can grow up to 90 cm in height 
and 5 mm in width. The leaves, stems and roots of C. citratus are commonly used in herbal medicine [8, 30]. 
Fresh C. citratus leaves contain about 0.4% essential oil. The essential oil contains citral α (~40%), citral β 
(~32%), nerol (~4.18%), geranicol (~3.04%), citronellal (~2.10%), terpinolene (~1.23%), geranyl acetate 
(~0.83%), myrecene (~0.72%), terpinol (~0.45%), methylheptenone (~0.2%), borneol (~0.1-0.4%), 
lanilylacetate (~0.1%), α-pinene (~0.07%) and β-pinene (~0.04%) [13, 29]. Geographical variations in some 
chemical constituents of C. citratus have been noted. Geraniol is the main substance found in essential oil of 
Ethiopian C. citratus; constituting about 40%, followed by 13% citral and 12% α-oxobisabolene. A variation 
was also noted in West and East Indian C. citratus leaf extract content of myrcene [1, 9]. Ethiopian C. citratus 
based formulation showed a comparable in-vitro acaricidal effect on the sheep ked (Melophagus Ovinus) as 
compared with the standard ivermectin at 1.565μl per ml. Superior mange mite mortality was observed at 
0.15625% C. citratus (in-vitro) than diazinon (0.1%) and ivermectine (0.01%). Higher mortality of lice 
(Damalinaovis) was observed at C. citratus 0.625% than the standard diazinon 0.1% [2]. A study by 
Ademuyiwa and his colleagues (2015) concluded as aqueous extract of C. citratus exhibits nephroprotective 
effect in wistar albino rats. A study in Nigeria indicated that aqueous leaves extracts of C. citratus has anti 
hepatotoxic action against cisplatin induced hepatic oxidative damage in rats. This might show free radical 
scavenging property of the plant leaves extract [10]. The aqueous leaf extract of C. citratus at 250 and 
500mg/kg resulted in a significant decrease on serum total cholesterol and LDL (Low Density Lipoprotein) in 
dose related fashion, and also significantly increased HDL compared to the control [7]. Daily treatment for 12 
weeks with C. citratus based formulation prepared using tween-80 emulsifier did not show any toxicity related 
mortalities and changes in general health, behavior, motor activities and growth. The formulation also did not 
produce toxic effect on hematological and biochemical assays [17]. The formulation was found to have strong 
acaricidal property against the aforementioned ectoparasites. It is prepared using less costly and easily accessed 
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excipient in order to minimize the production costs by the manufacturer. This could facilitate affordable quality 
and safe product for the small scale farmers. Therefore, this study attempts to investigate the safety of the new 
product on the rational basis to recommend for industrial scale production. 
2. Materials and Methods 
2.1 Study type: Experimental study 
2.2 Study design 
Sub-chronic toxicity study for three months was conducted on mice model. The doses of formulation at 1.25% 
and 3.75% of 1ml/100g were used. All animals were inspected for signs of morbidity and mortality (changes in 
skin, eyes, occurrence of secretions and excretions, lacrimation, pilorection, pupil size, unusual respiratory 
pattern and behavioral patterns like observations of tremors, convulsions, salivation, diarrhea, lethargy, sleep 
and coma).  Parameters like body weights, blood cell indices, serum biochemical levels, liver and kidney gross 
pathology and histopathology were also evaluated. 
2.3 Study setting 
The study was conducted at Addis Ababa University, College of Health Sciences, School of Medicine, 
Department of Anatomy (Histology laboratory) and Traditional and Modern Medicine Research Directorate of 
Ethiopian Public Health Institute (Pharmacology laboratory). 
2.4 The formulation: preparation and dilution 
Essential oil was extracted from C. citratus leaves using hydro distillation; and fixed oil from J. curcas seed by 
pressing in Wondogenet Agricultural Research Center. Anti ectoparasitic formulation with active ingredient of 
15% C. citratus essential oil, 3% fixative oil of J. curcas, 15% Geronol MS emulsifier with distilled water was 
prepared. Doses for administration were prepared every three days using 1.25% and 3.75% concentrations.  
2.5 Experimental animal preparation and grouping 
Healthy inbreed Swiss albino mice weighing 20 to 25g were obtained from animal breeding facility of Ethiopian 
Public Health Institute (EPHI). The animals were acclimated to laboratory conditions for seven days before the 
study started. They were kept at standard EPHI pharmacology laboratory with a recommended temperature and 
humidity by Organization for Economic Cooperation and Development (OECD). The room light was artificially 
adjusted at twelve hours light and twelve hours dark. They were fed with conventional laboratory diets with 
unlimited supply of drinking water [26]. The study was conducted on a total of 18 healthy, non pregnant and 
nulliparas’ female and male adult mice. The animals were assigned randomly in to three groups (GI, GII and 
GIII) each with six mice (three males and three females). They were kept separately in labeled aluminum cages 
to facilitate identification of the experimental groups. All mice in the same group and with the same sex were 
labeled on their tail by permanent marker color for the sake of differentiating one animal from the other. 
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2.6 Dose selection, dosing and duration of treatment 
All animals were restricted from food and water for 3 to 4 hours prior to administration, and their body weight 
were recorded [26]. The C. citratus based formulation (test preparation) and distilled water (control) dose for 
each animal in both treatment and control group was calculated based on their body weight. The treatment 
groups: GI and GII were given C. citratus based formulation orally by gastric intubation at the dose of 1.25% 
and 3.75% of 1ml per 100g respectively for 3 months. The control group (GIII) animals were given distilled 
water 1ml per 100g. Oral toxicity is used by considering incidental ingestions of the formulation by human and 
other animals. 
2.7 Data Collection 
After administration, all animals were observed continuously for two hours daily for any sign of toxicity. The 
body weight of each mouse was recorded on the 1
st 
day (before administration), and then every week throughout 
the experiment. Blood was collected from jugular vein in to two separate test tubes; with anti coagulant EDTA 
(Ethylene Diamine Tetra Acetate) and the other without anti coagulant. The blood sample with anti coagulant 
was immediately mixed with EDTA coated on the wall of the tube. The hematological parameters like: Red 
Blood Cell (RBC), White blood cell (WBC), Hemoglobin (HGB), Hematocrit (HCT), Mean Corpuscular 
Volume (MCV), Mean Corpuscular Hemoglobin (MCH), Mean Corpuscular Hemoglobin Concentration 
(MCHC) and platelet count were determined using automated hematological analyzer, Sysmex XT-1800i 
(Sysmex Corporation, Japan). For biochemical analysis, the blood samples in the test tubes without anti 
coagulant were centrifuged at 5000 rpm for 15 minutes using a bench top centrifuge Humax-HK (Human-
GmbH, Germany). The serum level of Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT), 
Aspartate Aminotransferase (AST), total bilirubin, totalcholesterol, triglyceride, Low density lipoprotein (LDL), 
High density lipoprotein (HDL), urea, uric acid and creatinine were determined using automated chemistry 
machine, Cobas Integra 400 plus Analyzer (ROCH Diagnostics, Japan). The animals were sacrificed by cervical 
dislocation, and subjected to careful examination of the external surface of the body, abdominal cavities and 
their contents. The liver and kidneys of the experimental animals were excised and fixed in 10% neutral 
buffered formaldehyde solution for 24 hours. 
2.8 Histological specimen preparation 
The liver and kidneys were washed several times with tap water to remove excess fixatives following overnight 
fixation in 10% formaldehyde solution. Both tissues were dehydrated with increasing concentration of ethanol 
70, 80, and 90%, respectively for two hours each, followed by absolute alcohol: group I, II and III, for one and 
half hour for each, and group IV overnight. The tissue samples were then cleared with xylene-I for two and half 
hours and xylene-II for one and half hour consecutively.  This was followed by impregnation in paraffin wax: 
wax-I for one and half hours, wax-II for two and half hours, and wax-III overnight. Finally, the tissue samples 
were embedded into tissue block by putting them in squares of metal plates by carefully pouring molten paraffin 
over them. The tissue blocks were sectioned at a thickness of 3 to 5μm and stained using routine H&E method. 
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2.9 Light microscopy and photomicrography  
The prepared tissue sections were carefully examined under binocular compound light microscope (Leica DM 
750, Germany). Tissue sections from the treated groups were examined for any evidence of changes in their 
architecture due to toxicities compared to the control. Some of the slides were then selected from both treatment 
and control groups; and photomicrographs were taken by EVOS microscope with integrated built-in high 
resolution digital camera (AMG, USA). The images were taken at ×10 and ×20 magnifications for 
documentation of the findings. 
2.10 Statistical analysis 
All data were organized and checked for completeness, and analyzed by one way ANOVA, using SPSS version 
21 computer software. The possible mean difference in body weight, hematological and biochemical values 
were identified. Then, it is followed by Dunnett’s t-test to compare the difference between control and treated 
groups, and determine their level of significance. All data are expressed as mean ± SEM (Standard Error of 
Mean). Differences at p<0.05 were considered to be statistically significant. 
2.11 Ethical consideration 
The study was conducted following the approval by the graduate committee of Department of Anatomy, School 
of Medicine, College of Health Sciences; Addis Ababa University. Animals used in this study were protected 
from any unnecessary pain and terrifying situations. They were also protected from any pathogens by keeping in 
appropriate and safe environment according to OECD guideline. 
2.12 Study period 
The study were conducted from May, 2016 to July 2017 
3. Results                    
3.1 Effect of the formulation on behavior, gross pathology and body weight 
The animals treated with the two doses (1.25% and 3.75%) of C. citrates based formulation did not show any 
toxicity related sign throughout the study period. No change was observed on the general behavior of the 
treatment groups as compared to the control. No animal death and significant variation in size, texture and color 
of internal organs (liver and kidney) were noted compared with the control group. Both treatment group animals 
had shown less mean body weight gain compared with the control. However, mean body weight of animals 
under the treatment of high dose (3.75%) showed significantly less weight gain (p< 0.05) only at week twelve as 
compared with the control group (Figure 1). 
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Figure 1: Comparison of effect of C. citratus based formulation on body weight of treated and 
control groups. Note: Significant weight change (p< 0.05) in 3.75% of the formulation on week 12 
compared to control.  
3.2 Effect of the formulation on different blood cell indices 
The three months administration of C. citratus based formulation at both doses did not produce significant 
change on any of the blood cell parameters as compared to the control (Table 1).   
Table 1: Effect of C. citratus based formulation on blood cell parameters of mice in  the sub-chronic 
toxicity study. 
Blood cell parameters  
  Distilled water                              C. citratus 
  1ml/100g 
    (G-III) 
11.25% CC 1ml/100g      
              (G-I) 
3.75% CC 1ml/100g 
(G-II)   
 
WBC ( х103 cells/mm3) 
 
4.28 ± 0.64  
 
4.45 ± 0.93 (0.97) 
 
4.02± 0.33 (0.94) 
RBC ( х106 cells/mm3) 9.90± 0.31  9.19± 0.55 (0.38)  9.85 ± 0.32 (0.99) 
HGB (gm/dl) 16.83± 0.18  16.20± 0.96 (0.68) 17.37± 0.33 (0.76) 
HCT (%)  50.50± 0.56  47.10± 2.38 (0.26) 49.72± 1.31 (0.91) 
MCV (fL)  53.10 ± 0.53  52.80 ± 0.66 (0.92) 53.03± 0.76 (0.99) 
MCH (pg/cell)  17.18± 0.68  17.65± 0.23 (0.68) 17.68± 0.27 (0.65) 
MCHC (gm/dl) 34.11± 0.44  34.37± 0.33 (0.83) 35.23± 0.24 (0.06) 
Platelet (х103 cells/mm3) 919.00± 137.87  683.00± 203.39 (0.58) 824.00± 210.56 (0.91) 
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 Values are expressed as Mean ± SEM. The figures in brackets indicate the calculated p values of the 
treatment groups as compared to the control.   
3.3 Effect of the formulation on serum biochemical levels 
In the serum biochemical levels: total cholesterol level  increased respectively by 26.1% and 59.8%, and LDL 
by 166.8% and 304.1%, at the 1.25% and 3.75% doses of the formulation as compared with the control, which 
were statistically significant (p< 0.05) (Figure 2). On the contrary, levels of creatinine were significantly 
reduced (p< 0.05) by 42.9% and 49.8%, respectively, at both 1.25% and 3.75% doses of the formulation (Table 
2). On the other hand, significant reduction (p< 0.05) in the serum levels of triglyceride by 24.9% and HDL by 
18.89% were observed. Significant increase in uric acid level by 92.93% was recorded at the higher dose 
(3.75%) of the formulation as compared with the control. In all the remaining biochemical tests investigated, the 
values were not significantly different from the control group at both low and high doses of the formulation 
(Table 2 and Figure 2). 
Table2: Effect of C. citratus based formulation on serum biochemical parameters in the sub -chronic 
toxicity study. 
 
 Values are expressed as Mean ± SEM. The figures in brackets indicate the calculated p values of the 
treatment groups as compared to the control.   
 *: Significantly different (p < 0.05) from the control. 
 
 
Serum biochemical 
indices 
 
 Distilled water  
1ml/100g  
 (G-III) 
                         C. citratus 
1.25% CC 1ml/100g  
(G-I) 
 
3.75% CC 1ml/100g 
 (G-II) 
    
ALT (IU/L) 98.83 ± 14.95                101.33± 21.04 (0.99)  50.00 ± 2.81 (0.06) 
ALP  (IU/L) 66.00± 10.47  53.33± 3.58 (0.30) 55.67± 1.17 (0.43) 
Bilirubin (mg/dl) 0.10± 0.01  0.10± 0.009 (0.89) 0.08± 0.002 (0.366) 
 Creatinine (mg/dl) 0.13 ± 0.01  0.076 ± 0.002 (0)*
 
0.066± 0.002 (0)* 
Urea (mg/dl) 54.30± 2.97  46.80± 2.59 (0.65) 66.03± 10.93 (0.38) 
   Uric acid (mg/dl) 2.97± 0.52  3.00± .88 (0.99) 5.73± 0.02 (0.009)* 
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Figure 2: Effect of C. citratus based formulation on serum lipid profile level in mice.  
**: Significantly different (p < 0.05) from the control.  
3.4 Effect of the formulation on histology of the liver 
Liver section of the control group animals showed normal indistinct lobules with the central vein in the middle. 
At the corners, there were portal triads, consisting of branches of the hepatic artery, portal vein and bile duct. 
Hepatocytes with central nuclei were seen radiating away from the central veins to the periphery. There is no 
blood vessel congestion, necrosis and degenerative conditions of hepatocytes (Figures 3A&3B).  In treatment 
group animals: normal architecture of the central veins, portal triads and hepatocytes were observed in the 
histopathological examination of the liver. No degenerative conditions and necrotic changes were observed. 
However, the liver tissue sections of animals in this group showed few pyknotic nuclei; and mononuclear 
infiltrations around central vein and portal triads (Figures 3 C; 3D; 3 E & 3F).   
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Figure 3: Photomicrographs of liver sections of mice in the control (Figures 3: A & B), mice 
treated with 1.25% (C & D) and 3.75% (E & F) of the C. citratus based formulation.CV = central 
vein, PV= portal vein, BD= bile duct, HA= hepatic artery, S= sinusoids, I= leucocytic infiltration, 
PK= pyknotic nucleus. Note: Some mononuclear infiltrations around central vein and portal triads 
in the mice treated with 1.25% of the formulation (figures 3: C & D).  Pyknosis and mononuclear 
infiltrations adjacent to portal triads in mice treated with 3.75% of the formulation  (Figures 3: E & 
F). (Sections were stained with H&E, x20).  
3.5 Effect of the formulation on histology of the kidney 
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The renal histopathology of the control group animals treated with distilled water showed renal corpuscles with 
normal size urinary space, normal glomerulus, and tubular structures. There is no congestion and sign of tubular 
necrosis as observed (Figure 4 A).    Normal renal corpuscle with normal glomerulus, urinary space and tubular 
systems were observed during the histopathological examination of the kidney tissue for animals treated with 
both doses of the formulation. There was also no tissue necrosis and capillary congestion of renal histology at 
both doses. However mononuclear leucocytic infiltrations were observed adjacent to tubules and Bowman’s 
capsule in kidney sections of animals with both treatment groups (Figures 4 B and 6 C). 
 
Figure4: Photomicrographs of kidney sections of mice in the control ( Fig. 4: A), mice treated with 
1.25% (C) and 3.75% (B) of the C. citratus based formulation. DT= distal convoluted tubule, PT= 
proximal convoluted tubule, MD = macula densa, BS = bowman’s  space, G=glomerulus. Note: 
Mononuclear infiltration of renal parenchyma adjacent to tubules and Bowman’s capsule in the 
kidney sections of animals with both treatment groups  (Figures 4: B & C). (Sections were stained 
with H&E, x20). 
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4. Discussion 
Different parts of plants, and their products for herbal medicine considered effective are not safe and free of 
adverse effects [15]. The primary aim of toxicological tests of herbal medicines are identifying adverse effects 
and determining their safety level [18].  In the current subchronic toxicity study of C. citratus based 
formulation; there was no any toxicity related sign, change on general behavior and animal death observed 
throughout the study period. No variation of size, texture and color on liver and kidney compared with the 
control group. This is consistent with G/Mickael and his colleagues (2017) report that employed C. citratus 
formulation with tween-80 emulsifier. Both treatment group animals showed less weight gain compared with the 
control. However, only significant weight change (p< 0.05) was observed at the end of the study (week twelve) 
in the group treated by 3.75% of the formulation. The same effect was observed on the study conducted by 
Adeneye and Agbaje, (2007). This might be due to high content of tannins in the lemon grass which is expected 
to reduce feed efficiency and weight gain [27], and the effect of J. curcas seeds in decreasing total food intake 
and resulting in lower weight gain [12]. Similar with G/Mickael and his colleagues (2017) the current toxicity 
study on different blood cell parameters showed no significant difference from the control group animals. These 
findings may indicate that there is no effect of the formulation on hematopoiesis, destruction and shrinkage of 
RBCs and immune boosting. In this study serum levels of ALT and bilirubin were slightly increased at 1.25% of 
the formulation and decreased at 3.75% of the formulation. AST and ALP in both treatment groups showed a 
decrease from the control. But none of the changes in the above liver function parameters were found significant 
(p> 0.05) compared to the control.  A study conducted on rats administered with aqueous extract of C. citratus 
had shown a significant decrease on serum total cholesterol and LDL in dose related fashion, and at the same 
time significantly increased HDL (p< 0.05), compared to the control [7]. Study by Ademuyiwa and his 
colleagues (2014) on ethanolic extract of the plant resulted in significant decrease (p< 0.05) of total cholesterol, 
triglyceride, HDL and LDL levels compared with the aqueous extract treated and control group rats. However, 
aqueous extract did show significant decrease in LDL compared with the control. In contrary with all these 
findings, the current study showed significant increase in total cholesterol and LDL levels at both doses, but the 
triglyceride and HDL showed a significant decrease only at high dose (3.75% of the formulation) compared to 
the control.  The reason behind all these discordance could be variation in dose, extract type, duration of the 
treatment, animal type, and geographic variation in chemical constituent of the plant. Nevertheless, the findings 
from the present study may argue with the recommendations from different researchers that C. citratus is 
important to decrease blood level of bad cholesterols and risk of cardio vascular diseases, and call for further 
investigation at different conditions. Many results on the effect of different preparations of C. citratus on renal 
system in different type of animals are conflicting [17, 19 25, 28, 30]. In the present study, level of uric acid in 
animals treated with 3.75% of the formulation showed significant increase (p< 0.05) compared with the control. 
This might show the effect of prolonged treatment with high dose of C. citratus based formulation on purine 
metabolism or renal excretion of uric acid. The difference in clinical parameter indices like creatinine and urea 
at both doses of the formulation did not show significant increment compared to the control. This is consistent 
with reports of G/Mickael and his colleagues (2017) and Ademuyiwa and his colleagues (2016). Discrepancies 
of the findings from different reports may emanate from differences in one or more of: administered doses, 
duration of treatment, extraction type, age of plant at harvest, and geographical variations in chemical 
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constituents of the essential oil. The histopathological examination of tissues and organs is best for evaluating 
treatment related pathological changes which further confirms the alteration in their cellular structure. In the 
current study, liver histopathologies of both treatment groups and control group animals are almost the same 
with normal morphology of hepatocytes, central vein and portal triads. There is no sign of necrosis. However, in 
both treatment group animals’ tissue sections, insignificant leucocytic infiltrations were observed adjacent to 
portal triads and central veins. There were also few hepatocytes with pyknotic nuclei in animals treated with 
3.75% of the formulation.  The study conducted on rats treated with ethanolic and aqueous extract of C. citratus, 
histopathological results showed no degenerative conditions in the liver [6]. However, essential oil from the 
plant leaves with doses higher than 1,500 mg/kg showed histological changes in the liver, leading to marked 
abnormalities in the liver of treated rats [16].  These findings may suggest as C. citratus is safe at low doses, but 
prolonged treatment and high dose could be toxic on this vital organ.  According to Ademuyiwa and his 
colleagues (2016), histological examination of kidney from rats treated with doses of 200, 500, 1000, 2000, 
4000 and 5000 mg/kg body weights of ethanolic extract of C. citratus showed no adverse effects on the 
histology of the tissue. Similar to G/Mickael and his colleagues (2017) the current study findings showed no 
tissue necrosis and capillary congestion, but insignificant peritubular mononuclear cellular infiltrations in both 
treatment group animals.  In agreement with the values of liver and renal function biochemical tests observed; 
the findings in the histopathological study suggest for no noticeable toxicity of the current formulation on both 
organs at present settings of study. 
5. Limitation of the study 
The toxic effect of the formulation on gastro intestinal and other visceral organs, and higher experimental 
animals is not considered. 
6. Conclusion and Recommendations 
This sub-chronic toxicity of C. citratus based formulation showed no noticeable gross toxicity. There was no 
significant difference in the blood cell parameters, histopathology and majority of biochemical parameters for 
liver and kidney functions. However, it is important to consider the effect of the formulation in prolonged 
treatment on: body weight, uric acid excretion and lipid metabolism. Also it is recommended to consider further 
toxicological effect of the formulation on different visceral organs, and in higher non rodent species. 
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 Appendix 
A. Preparation of working solutions  
Eq. (A.1). 10% Neutral Buffered Formalin 
 40% formaldehyde---------------------------------------------------------- 100ml  
 Distilled water--------------------------------------------------------------- 900ml  
 Sodium di-hydrogen phosphate monohydrate------------------------- 4gm  
 Disodium hydrogen phosphate anhydrous----------------------------- 6.5gm  
Eq. (A.2). Harris’s Hematoxylin (H)  
 Hematoxylin crystals---------------------------------------------------------- 2.5gm  
 Absolute alcohol--------------------------------------------------------------- 25ml  
 Potassium alum---------------------------------------------------------------- 50gm  
 Distilled water----------------------------------------------------------------- 500ml  
 Sodium iodate----------------------------------------------------------------- 0.5gm  
 Glacial acetic acid------------------------------------------------------------- 20ml  
Eq. (A.3). 1% Alcoholic Eosin (E)  
 Eosin Y, water soluble (CI 45380)------------------------------------------ 1gm  
 95% Ethanol-------------------------------------------------------------------- 100ml  
 Glacial acetic acid------------------------------------------------------------- 0.5ml  
Eq. (A.4). 1% Acidic alcohol  
 70% alcohol--------------------------------------------------------------------- 500ml  
 Hydrochloric acid, concentrated---------------------------------------------- 5ml  
Eq. (A.5). Bluing solution  
 Sodium bicarbonate------------------------------------------------------------ 2.5gm  
 Distilled water------------------------------------------------------------------ 1000ml 
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B. Tissue processing procedures 
Eq. (B.1). Fixation 
 10% Neutral Buffered Formalin----------------- 24 hrs  
Eq. (B.2). Washing   
 Tap water-------------------------------------------- several changes  
Eq. (B.3). Dehydration 
 70% Ethanol----------------------------------------- 2 hrs  
 80% Ethanol----------------------------------------- 2 hrs  
 90% Ethanol ---------------------------------------- 2 hrs  
 Absolute alcohol I---------------------------------- 1 and 1/2 hrs  
 Absolute alcohol II--------------------------------- 1 and 1/2 hrs  
 Absolute alcohol III-------------------------------- 1 and 1/2 hrs  
 Absolute alcohol IV-------------------------------- overnight  
Eq. (B.4). Clearing  
 Xylene- I -----------------------------------------------1 and 1/2 hrs  
 Xylene- II--------------------------------------------- 2 and 1/2 hrs  
Eq. (B.5). Infiltration  
 Paraffin wax- I……………………………….. 1 and 1/2 hrs  
 Paraffin wax- II------------------------------------- 2 and 1/2 hrs  
 Paraffin wax- III------------------------------------ overnight 
C.  Hematoxylin and Eosin, Tissue Staining Protocol  
Eq. (C.1). De-paraffinization  
 Xylene- I--------------------------------------------------------- 4 min  
 Xylene- II-------------------------------------------------------- 4 min  
Eq. (C.2). Rehydration  
 Absolute alcohol I---------------------------------------------- 4 min  
 Absolute alcohol II--------------------------------------------- 4 min  
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 95% Ethanol----------------------------------------------------- 3min  
 80% Ethanol----------------------------------------------------- 3 min  
 Rinse in distilled water----------------------------------------- 5 min  
 Stain in Hematoxylin------------------------------------------ 10 min  
 Rinse in running tap water------------------------------------- 5 min  
 Decolorize in acid alcohol------------------------------------- 1-3 sec  
 Rinse in running tap water------------------------------------- 5 min  
 Immerse in Sodium bicarbonate solution-------------------- 1 min  
 Rinse in running tap water------------------------------------- 5 min  
 Counter stain in Eosin------------------------------------------ 1 min  
Eq. (C.3). Dehydration  
 80% Ethanol------------------------------------------------------ 3 min  
 95% Ethanol------------------------------------------------------ 3 min  
 Absolute alcohol II---------------------------------------------- 3 min  
 Absolute alcohol I----------------------------------------------- 3 min  
Eq. (C.4). Clearing  
 Xylene II---------------------------------------------------------- 3 min  
 Xylene I----------------------------------------------------------- 3 min 
D. Dilution of stock solution and Preparation of volume for administration 
Eq. (D.1). Dilution of stock solution 
 C1V1=C2V2 
1. C1……………Concentration of stock solution 
2. V1……………Volume required 
3. C2……………Concentration to be prepared 
4. V2……………Volume of solution to be prepared 
o C1= 15%        
o V1=? 
o C2= 1.25% 
o V2= 10ml 
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 15% × V1 = 1.25 × 10ml 
 0.8ml of stock solution + 9.2ml of distilled water. 
 C1V1=C2V2 
o C1= 15%        
o V1=? 
o C2= 3.75% 
o V2= 10ml 
 15% × V1 = 3.75% × 10ml 
 2.5ml of stock solution + 7.5ml of distilled water. 
Eq. (D.2). Preparation of volume for administration 
 The formulation for administration is 1ml/100g body weight of mouse. 
   
 
